A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Precision medicine platform Caris Life Sciences (CAI) priced above the upwardly revised range to raise $494 million at a $6.1 billion market cap. Caris is...read more
Jyong Biotech, a commercial-ready Taiwanese biotech developing therapies for urinary diseases, raised $20 million by offering 2.7 million shares at $7.50, the low end of the range of $7.50 to $8.50. Jyong Biotech is focused on developing and commercializing...read more
Jyong Biotech, a commercial-ready Taiwanese biotech developing therapies for urinary diseases, announced terms for its IPO on Thursday. The New Taipei City, Taiwan-based company plans to raise $19 million by offering 2.4 million shares at a price range of...read more
Jyong Biotech, a commercial-ready Taiwanese biotech developing therapies for urinary diseases, filed on Thursday with the SEC to raise up to $29 million in an initial public offering. The company had previously filed in August 2023 to raise $40 million, but...read more
US IPO Weekly Recap: Sizable precision medicine and insurance IPOs raise a combined $902 million
A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Precision medicine platform Caris Life Sciences (CAI) priced above the upwardly revised range to raise $494 million at a $6.1 billion market cap. Caris is...read more
Urinary disease biotech Jyong Biotech prices US IPO at $7.50, the low end of the range
Jyong Biotech, a commercial-ready Taiwanese biotech developing therapies for urinary diseases, raised $20 million by offering 2.7 million shares at $7.50, the low end of the range of $7.50 to $8.50. Jyong Biotech is focused on developing and commercializing...read more
Urinary disease biotech Jyong Biotech sets terms for $19 million US IPO
Jyong Biotech, a commercial-ready Taiwanese biotech developing therapies for urinary diseases, announced terms for its IPO on Thursday. The New Taipei City, Taiwan-based company plans to raise $19 million by offering 2.4 million shares at a price range of...read more
Urinary disease biotech Jyong Biotech refiles for a $29 million US IPO
Jyong Biotech, a commercial-ready Taiwanese biotech developing therapies for urinary diseases, filed on Thursday with the SEC to raise up to $29 million in an initial public offering. The company had previously filed in August 2023 to raise $40 million, but...read more